PYRIDOPYRIMIDINES AND METHODS OF THEIR USE
Disclosed are compounds useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases.
1 - 215 . (canceled)
216 . A compound chosen from compounds of Formula I or pharmaceutically acceptable salts thereof:
wherein:
X 1 is chosen from N or CR 1 ;
X 2 is chosen from N or CR 2 ;
X 3 is chosen from N or CR 3 ;
X 4 is chosen from N or CR 4 ;
R 5 is chosen from one of the following:
L 1 is chosen from an optionally substituted C 1-9 heteroarylene group having at least one 5-membered ring, an optionally substituted non-aromatic C 1-9 heterocyclylene group, or one of the following:
R 6 is chosen from an optionally substituted C 1-6 alkyl group, an optionally substituted C 6-10 aryl group, an optionally substituted C 3-10 carbocyclyl group, an optionally substituted C 1-9 heteroaryl group, an optionally substituted C 1-9 heterocyclyl group, or an optionally substituted C 1-6 alkylene-C 1-9 heterocyclyl group;
alternatively, L 1 and R 6 together may form an optionally substituted C 2-9 oxyheteroaryl group, an optionally substituted pyrimidin-r-yl group, or an optionally substituted pyrid-2-yl group;
R 1 is chosen from hydrogen, a halogen atom, or an optionally substituted C 1-6 alkyl group;
R 2 is hydrogen;
R 3 is chosen from hydrogen, a halogen atom, an optionally substituted C 1-6 alkyl group, or
R 4 is chosen from hydrogen, a halogen atom, or an optionally substituted C 1-6 alkyl group;
L 2 is absent or is chosen from one of the following:
R 7 is chosen from an optionally substituted C 6-10 aryl group, an optionally substituted C 3-10 carbocyclyl group, an optionally substituted C 1-9 heteroaryl group, or an optionally substituted C 1-9 heterocyclyl group;
R N1 , R N2 , and R N3 , which may be the same or different, are independently chosen from hydrogen or an optionally substituted C 1-6 alkyl group; and
m is 0, 1, 2, or 3;
with the proviso that only one of X 1 , X 2 , X 3 , and X 4 is N.
217 . A composition comprising a compound according to claim 216 and a pharmaceutically acceptable excipient.
218 . A method of treating a neurological disorder in a patient in need thereof, the method comprising administering to the patient an effective amount of a compound according to claim 216 to the patient.
219 . The method according to claim 218 , wherein the neurological disorder is FTLD-TDP, chronic traumatic encephalopathy, ALS, Alzheimer's disease, LATE, or frontotemporal lobar degeneration.
220 . A method of inhibiting toxicity in a cell related to a protein, the method comprising contacting the cell with a compound according to claim 216 .
221 . The method according to claim 220 , wherein the toxicity is TDP-43-related toxicity or C9orf72-related toxicity.
222 . A method of inhibiting PIKfyve in a cell expressing PIKfyve protein, the method comprising contacting the cell with a compound according to claim 216 .
223 . A compound chosen from compounds of Formula II, Formula III, Formula IV, Formula V, or pharmaceutically acceptable salts thereof:
wherein:
R 1 is chosen from hydrogen, a halogen atom, or an optionally substituted C 1-6 alkyl group;
R 2 is chosen from hydrogen, a halogen atom, or an optionally substituted C 1-6 alkyl group;
R 3 is chosen from hydrogen, a halogen atom, an optionally substituted C 1-6 alkyl group, or
R 4 is chosen from hydrogen, a halogen atom, or an optionally substituted C 1-6 alkyl group;
R 5 is chosen from one of the following:
L 1 is chosen from an optionally substituted C 1-9 heteroarylene group having at least one 5-membered ring, an optionally substituted non-aromatic C 1-9 heterocyclylene group, or one of the following:
R 6 is chosen from an optionally substituted C 1-6 alkyl group, an optionally substituted C 6-10 aryl group, an optionally substituted C 3-10 carbocyclyl group, an optionally substituted C 1-9 heteroaryl group, an optionally substituted C 1-9 heterocyclyl group, or an optionally substituted C 1-6 alkylene-C 1-5 heterocyclyl group;
alternatively, L 1 and R 6 together may form an optionally substituted C 2-9 oxyheteroaryl group, an optionally substituted pyrimidin-r-yl group, or an optionally substituted pyrid-2-yl group;
L 2 is absent or is chosen from one of the following:
R 7 is chosen from an optionally substituted C 6-10 aryl group, an optionally substituted C 3-10 carbocyclyl group, an optionally substituted C 1-9 heteroaryl group, or an optionally substituted C 1-9 heterocyclyl group;
R N1 , R N2 , and R N3 , which may be the same or different, are independently chosen from hydrogen or an optionally substituted C 1-6 alkyl group; and
m is 0, 1, 2, or 3.
224 . A composition comprising a compound according to claim 223 and a pharmaceutically acceptable excipient.
225 . A method of treating a neurological disorder in a patient in need thereof, the method comprising administering to the patient an effective amount of a compound according to claim 223 to the patient.
226 . The method according to claim 225 , wherein the neurological disorder is FTLD-TDP, chronic traumatic encephalopathy, ALS, Alzheimer's disease, LATE, or frontotemporal lobar degeneration.
227 . A method of inhibiting toxicity in a cell related to a protein, the method comprising contacting the cell with a compound according to claim 223 .
228 . The method according to claim 227 , wherein the toxicity is TDP-43-related toxicity or C9orf72-related toxicity.
229 . A method of inhibiting PIKfyve in a cell expressing PIKfyve protein, the method comprising contacting the cell with a compound according to claim 223 .
230 . A compound chosen from compounds 1-88 or pharmaceutically acceptable salts thereof:
231 . A composition comprising a compound according to claim 230 and a pharmaceutically acceptable excipient.
232 . A method of treating a neurological disorder in a patient in need thereof, the method comprising administering to the patient an effective amount of a compound according to claim 230 to the patient.
233 . The method according to claim 232 , wherein the neurological disorder is FTLD-TDP, chronic traumatic encephalopathy, ALS, Alzheimer's disease, LATE, or frontotemporal lobar degeneration.
234 . A method of inhibiting toxicity in a cell related to a protein, the method comprising contacting the cell with a compound according to claim 230 .
235 . The method according to claim 234 , wherein the toxicity is TDP-43-related toxicity or C9orf72-related toxicity.
236 . A method of inhibiting PIKfyve in a cell expressing PIKfyve protein, the method comprising contacting the cell with a compound according to claim 230 .